This is a U.S news story, published by CNBC, that relates primarily to Biogen news.
For more U.S news, you can click here:
more U.S newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
biotech company. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest multiple sclerosis products news, breakthrough Alzheimer news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
BiogenCNBC
•
87% Informative
Biogen reported third-quarter revenue and adjusted earnings that topped expectations.
The company also raised its full-year profit guidance.
Sales of its breakthrough Alzheimer's drug, Leqembi , helped offset a year-over-year decline in revenue for the company's multiple sclerosis products.
The treatment brought in $67 million in sales for the third quarter , including $39 million from the U.S ..
VR Score
93
Informative language
96
Neutral language
77
Article tone
formal
Language
English
Language complexity
45
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links